Compare RGEN & TXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGEN | TXG |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.0B |
| IPO Year | 1995 | 2019 |
| Metric | RGEN | TXG |
|---|---|---|
| Price | $181.13 | $65.12 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 15 |
| Target Price | ★ $167.67 | $20.25 |
| AVG Volume (30 Days) | 1.2M | ★ 3.0M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 286.96 | 76.97 |
| EPS | ★ 0.24 | N/A |
| Revenue | $141,236,000.00 | ★ $245,893,000.00 |
| Revenue This Year | $14.30 | N/A |
| Revenue Next Year | $14.52 | $7.33 |
| P/E Ratio | $751.21 | ★ N/A |
| Revenue Growth | 35.10 | ★ 68.06 |
| 52 Week Low | $100.99 | $11.17 |
| 52 Week High | $188.73 | $64.53 |
| Indicator | RGEN | TXG |
|---|---|---|
| Relative Strength Index (RSI) | 76.48 | 73.87 |
| Support Level | $156.65 | $17.54 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 6.79 | 3.85 |
| MACD | 1.81 | 0.73 |
| Stochastic Oscillator | 84.69 | 98.84 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).